文献速递脑血管病外科神经重症

耳迷走神经刺激减轻蛛网膜下腔出血后炎症与血管痉挛:单中心随机对照试验

Auricular vagus nerve stimulation for mitigation of inflammation and vasospasm in subarachnoid hemorrhage: a single-institution randomized controlled trial.
PubMed 文献 · J Neurosurg · 2025-01-24

该前瞻性三盲随机对照试验将27例蛛网膜下腔出血患者随机分为经耳迷走神经刺激(taVNS)组或假刺激组,每3天采集血和脑脊液检测炎症标志物。结果显示taVNS未发生不良事件,影像学血管痉挛显著减少(p=0.018),血管管径恢复正常更快(p<0.001),出院及首次随访时良好结局比例更高(38.4% vs 21.4%;76.9% vs 57.1%)。

要点

  • taVNS组影像学血管痉挛显著减少(p=0.018),血管管径恢复至正常更快(p<0.001)。
  • taVNS组血浆和脑脊液中肿瘤坏死因子-α及白细胞介素-6显著降低(p<0.05)。
  • taVNS组出院及首次随访良好结局比例高于假刺激组(38.4% vs 21.4%;76.9% vs 57.1%)。

核心结论

  • taVNS是一种无创的神经和全身免疫调节方法,本试验支持taVNS在蛛网膜下腔出血后可减轻炎症反应、减少影像学血管痉挛并可能改善功能和神经结局。

研究设计与样本

  • 前瞻性三盲随机对照试验,27例患者随机分配至taVNS组或假刺激组,每3天采集血和脑脊液样本定量炎症标志物,分析影像学脑血管痉挛严重程度和功能结局(改良Rankin量表评分)。

主要发现

  • 无不良事件发生;影像学血管痉挛显著减少(p=0.018),系列血管管径测量显示taVNS组较假刺激组更快恢复正常(p<0.001)。
  • taVNS组血浆肿瘤坏死因子-α在第7天和第10天显著降低,脑脊液肿瘤坏死因子-α在第13天显著降低;血浆白细胞介素-6在第4天显著降低,脑脊液白细胞介素-6在第13天显著降低(p<0.05)。
  • taVNS组出院时良好结局比例38.4% vs 假刺激组21.4%,首次随访时76.9% vs 57.1%。
  • taVNS组改良Rankin量表评分从入院至首次随访显著改善(p=0.014),假刺激组无显著改善(p=0.18)。
  • taVNS组出院转至专业护理机构或临终关怀机构的比率显著更低(p=0.04)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Inflammation contributes to morbidity following subarachnoid hemorrhage (SAH). The authors of this study evaluate how applying noninvasive transauricular vagus nerve stimulation (taVNS) can target this deleterious inflammatory response following SAH and reduce the rate of radiographic vasospasm. METHODS: In this prospective, triple-blinded, randomized controlled trial, 27 patients were randomized to taVNS or sham stimulation. Serial blood and CSF samples were collected every 3 days to quantify inflammatory markers. Radiographic cerebral vasospasm severity and functional outcomes (modified Rankin Scale scores) were analyzed. RESULTS: No adverse events occurred. Radiographic vasospasm was significantly reduced (p = 0.018), with serial vessel caliber measurements demonstrating a more rapid return to normal than in the sham-treated group (p < 0.001). In the taVNS group, tumor necrosis factor-α was significantly reduced in both plasma (days 7 and 10) and CSF (day 13); interleukin-6 was also significantly reduced in plasma (day 4) and CSF (day 13) (p < 0.05). Patients receiving taVNS had higher rates of favorable outcomes at discharge (38.4% vs 21.4%) and first follow-up (76.9% vs 57.1%). Patients treated with taVNS had significant improvement in modified Rankin Scale scores from admission to first follow-up (p = 0.014), unlike patients in the sham-treated group (p = 0.18). The taVNS group had a significantly lower rate of discharge to a skilled nursing facility or hospice (p = 0.04). CONCLUSIONS: taVNS is a noninvasive method of neuro- and systemic immunomodulation. This trial supports the finding that taVNS following SAH can mitigate the inflammatory response, reduce radiographic vasospasm, and potentially improve functional and neurological outcomes.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Huguenard AL, Tan G, Rivet DJ, et al. Auricular vagus nerve stimulation for mitigation of inflammation and vasospasm in subarachnoid hemorrhage: a single-institution randomized controlled trial. J Neurosurg. 2025. PMID: 39854697. doi:10.3171/2024.10.JNS241643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。